Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Matrix metalloproteinase-9 expression in mammary gland tumors in dogs and its relationship with prognostic factors and patient outcome.

Santos AA, Lopes CC, Marques RM, Amorim IF, Gärtner MF, de Matos AJ.

Am J Vet Res. 2012 May;73(5):689-97. doi: 10.2460/ajvr.73.5.689.

PMID:
22533401
2.

Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors.

Chang CC, Tsai MH, Liao JW, Chan JP, Wong ML, Chang SC.

J Am Vet Med Assoc. 2009 Aug 15;235(4):391-6. doi: 10.2460/javma.235.4.391.

PMID:
19681719
3.

Immunohistochemical evaluation of MMP-2 and TIMP-2 in canine mammary tumours: a survival study.

Santos A, Lopes C, Frias C, Amorim I, Vicente C, Gärtner F, Matos Ad.

Vet J. 2011 Dec;190(3):396-402. doi: 10.1016/j.tvjl.2010.12.003. Epub 2011 Jan 26.

PMID:
21269852
4.

Mammary gland tumors in male dogs.

Saba CF, Rogers KS, Newman SJ, Mauldin GE, Vail DM.

J Vet Intern Med. 2007 Sep-Oct;21(5):1056-9.

5.

Postoperative treatment outcome in canine mammary tumors. Multivariate analysis of the prognostic value of pre- and postoperatively available information.

Betz D, Schoenrock D, Mischke R, Baumgärtner W, Nolte I.

Tierarztl Prax Ausg K Kleintiere Heimtiere. 2012;40(4):235-42. English, German.

PMID:
22911254
6.

Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998-2002).

Chang SC, Chang CC, Chang TJ, Wong ML.

J Am Vet Med Assoc. 2005 Nov 15;227(10):1625-9.

PMID:
16313041
7.

Matrix metalloproteinases and their inhibitors in canine mammary tumors.

Aresu L, Giantin M, Morello E, Vascellari M, Castagnaro M, Lopparelli R, Zancanella V, Granato A, Garbisa S, Aricò A, Bradaschia A, Mutinelli F, Dacasto M.

BMC Vet Res. 2011 Jul 4;7:33. doi: 10.1186/1746-6148-7-33.

8.

Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours.

Santos A, Lopes C, Marques RM, Amorim I, Ribeiro J, Frias C, Vicente C, Gärtner F, de Matos A.

Vet J. 2011 Jul;189(1):43-8. doi: 10.1016/j.tvjl.2010.05.023. Epub 2010 Jul 2.

PMID:
20598596
9.

Quantitation of the Regional Lymph Node Metastatic Burden and Prognosis in Malignant Mammary Tumors of Dogs.

de Araújo MR, Campos LC, Ferreira E, Cassali GD.

J Vet Intern Med. 2015 Sep-Oct;29(5):1360-7. doi: 10.1111/jvim.13576. Epub 2015 Jun 30.

10.

Immunocytochemical study of Ki-67 as a prognostic marker in canine mammary neoplasia.

Zuccari DA, Santana AE, Cury PM, Cordeiro JA.

Vet Clin Pathol. 2004;33(1):23-8.

PMID:
15048623
11.

Identification of prognostic factors in canine mammary malignant tumours: a multivariable survival study.

Santos AA, Lopes CC, Ribeiro JR, Martins LR, Santos JC, Amorim IF, Gärtner F, Matos AJ.

BMC Vet Res. 2013 Jan 4;9:1. doi: 10.1186/1746-6148-9-1.

12.

Prognostic value of histologic stage and proliferative activity in canine malignant mammary tumors.

Sarli G, Preziosi R, Benazzi C, Castellani G, Marcato PS.

J Vet Diagn Invest. 2002 Jan;14(1):25-34.

PMID:
12680640
13.

Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables.

Peña LL, Nieto AI, Pérez-Alenza D, Cuesta P, Castaño M.

J Vet Diagn Invest. 1998 Jul;10(3):237-46.

PMID:
9683072
14.

Immunolocalization of the smooth muscle-specific protein calponin in complex and mixed tumors of the mammary gland of the dog: assessment of the morphogenetic role of the myoepithelium.

Espinosa Los de Monteros A, Millán MY, Ordás J, Carrasco L, Reymundo C, Martín Las de Mulas J.

Vet Pathol. 2002 Mar;39(2):247-56.

PMID:
12009063
15.

Expression and significance of CHIP in canine mammary gland tumors.

Wang H, Yang X, Jin Y, Pei S, Zhang D, Ma W, Huang J, Qiu H, Zhang X, Jiang Q, Sun W, Zhang H, Lin D.

J Vet Med Sci. 2015 Nov;77(11):1465-71. doi: 10.1292/jvms.14-0484. Epub 2015 Jul 9.

16.

Clinical and pathological prognostic factors in canine mammary tumors.

Pérez Alenza MD, Peña L, Nieto AI, Castaño M.

Ann Ist Super Sanita. 1997;33(4):581-5.

PMID:
9616968
17.

Prognostic value of vascular endothelial growth factor and hypoxia-inducible factor 1α in canine malignant mammary tumors.

Moschetta MG, Maschio LB, Jardim-Perassi BV, Gelaleti GB, Lopes JR, Leonel C, Gonçalves Ndo N, Ferreira LC, Martins GR, Borin TF, Zuccari DA.

Oncol Rep. 2015 May;33(5):2345-53. doi: 10.3892/or.2015.3856. Epub 2015 Mar 16.

PMID:
25779537
18.

Detection of matrix metalloproteinases in canine mammary tumours: analysis by immunohistochemistry and zymography.

Hirayama K, Yokota H, Onai R, Kobayashi T, Kumata T, Kihara K, Okamoto M, Sako T, Nakade T, Izumisawa Y, Taniyama H.

J Comp Pathol. 2002 Nov;127(4):249-56.

PMID:
12443732
19.

Immunohistochemical and molecular analysis of caveolin-1 expression in canine mammary tumors.

Zuccari DA, Castro R, Gavioli AF, Mancini UM, Frade CS, Leonel C.

Genet Mol Res. 2012 Jan 27;11(1):153-65. doi: 10.4238/2012.January.27.2.

20.

Influence of host factors on survival in dogs with malignant mammary gland tumors.

Philibert JC, Snyder PW, Glickman N, Glickman LT, Knapp DW, Waters DJ.

J Vet Intern Med. 2003 Jan-Feb;17(1):102-6.

Supplemental Content

Support Center